HER-2/neu Peptide Vaccine

DRACPC ID  DRACPC0098

Active Ingredients   HER-2/neu Peptide Vaccine

Description  A cancer vaccine comprised of peptides derived from the extracellular domain of the tumor-associated antigen Her-2/neu with potential antineoplastic activity. HER-2/neu peptide vaccine may induce antibodies with anti-tumor activity and may also elicit a specific CD8 T-cell response against specific tumor cell types.

Synonyms  HER-2/neu Helper-Peptide Vaccine; HER-2-Neu Peptide Vaccine; HER-2/neu Peptide Vaccine

Type  Biotech

Disease  Stage IV Breast Cancer, Stage IV Ovarian Cancer

Classification

  

Peptide and derivative

Structure Information


Molecular Formula  Not available

Molecular Weight  Not available

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  Not available

InChI  Not available

InChI_Key Not available

SMILES  Not available

External Codes


PubChem CID  Not available

DrugBank Accession Number  Not available

NCI Thesaurus Code  C2537  

UNII  Not available  

CAS  Not available



Drug approval


Drug indication
    Investigated for use/treatment in Stage IV Breast Cancer, Stage IV Ovarian Cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00194714 Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in Vivo HER2/Neu Positive; HLA-A2 Positive Cells Present; Stage IV Breast Cancer; Stage IV Ovarian Cancer Phase 1/2 Treatment
NCT00068614 A Phase I Trial Evaluating The Safety Of Intramuscular Injections Of HER-2 Protein AUTOVAC (PX104.1.6) In Patients With Breast Cancer Breast Cancer Phase 1 Treatment
NCT00005023 A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers Breast Cancer; Lung Cancer; Ovarian Cancer Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.